CYP2C9 and VKORC1 polymorphisms are differently distributed in the brazilian population according to self-declared ethnicity or genetic ancestry

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 8, 2012, Pages 957-963

  Soares, Renata Alonso Gadi ^a   Santos, Paulo Caleb Junior Lima ^a   MacHado Coelho, George Luiz Lins ^b   Nascimento, Raimundo Marques Do ^b   Mill, Jose Geraldo ^c   Krieger, Jose Eduardo ^a   Pereira, Alexandre Costa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^c FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; ENZYME; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1;

ADULT; ARTICLE; BRAZIL; CAUCASIAN; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; MALE; NEGRO; PHENOTYPE;

ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; BRAZIL; DNA PRIMERS; ETHNIC GROUPS; GENETICS, POPULATION; HUMANS; MIXED FUNCTION OXYGENASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 84865702002     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2012.0019     Document Type: Article

References (45)

1. Alvim RO, Freitas SR, Ferreira NE, et al. (2010) APOE polymorphism is associated with lipid profile, but not with arterial stiffness in the general population. Lipids Health Dis 9:128.
2. Botton MR, Bandinelli E, Rohde LE, et al. (2011) Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol 72:442-450.
3. Caldwell MD, Awad T, Johnson JA, et al. (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111:4106-4112.
4. Cavallari LH, Langaee TY, Momary KM, et al. (2010) Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 87:459-464.
5. Epstein RS, Moyer TP, Aubert RE, et al. (2011) Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 55:2804-2812.
6. Ferder NS, Eby CS, Deych E, et al. (2010) Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost 8:95-100.
7. Finkelman BS, Gage BF, Johnson JA, et al. (2011) Genetic warfarin dosing: tables versus algorithms. J AmColl Cardiol 57:612-618.
8. Gage BF, Eby C, Johnson JA, et al. (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84:326-331.
9. Geisen C, Watzka M, Sittinger K, et al. (2005) VKORC1 haplotypes and their impact on the inter-individual and interethnical variability of oral anticoagulation. Thromb Haemost 94:773-779.
10. Ginsburg GS, Voora D (2010) The long and winding road to warfarin pharmacogenetic testing. J Am Coll Cardiol 55:2813-2815.
11. Giolo SR, Soler JM, Greenway SC, et al. (2011) Brazilian urban population genetic structure reveals a high degree of admixture. Eur J Hum Genet 20:111-116.
12. Higashi MK, Veenstra DL, Kondo LM, et al. (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287:1690-1698.
13. Hirsh J, Dalen J, Anderson DR, et al. (2001) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119:8S-21S.
14. Jetter A, Kinzig-Schippers M, Skott A, et al. (2004) Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol 60:165-171.
15. Johnson JA, Cavallari LH, Beitelshees AL, et al. (2011) Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther 90:519-531.
16. Kirchheiner J, Ufer M, Walter EC, et al. (2004) Effects of CYP2C9 polymorphisms on the pharmacokinetics of R-and Sphenprocoumon in healthy volunteers. Pharmacogenetics 14:19-26.
17. Kitzmiller JP, Groen DK, Phelps MA, et al. (2011) Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med 78:243-257.
18. Klein TE, Altman RB, Eriksson N, et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753-764.
19. Landefeld CS, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95:315-328.
20. Lenzini P, Wadelius M, Kimmel S, et al. (2010) Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 87:572-578.
21. Li T, Lange LA, Li X, et al. (2006) Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet 43:740-744.
22. Limdi NA, McGwin G, Goldstein JA, et al. (2008) Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 83:312-321.
23. Limdi NA, Wadelius M, Cavallari L, et al. (2010) Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115:3827-3834.
24. Loebstein R, Dvoskin I, Halkin H, et al. (2007) A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109:2477-2480.
25. Makdisse M, Pereira AC, Brasil Dde P, et al. (2008) Prevalence and risk factors associated with peripheral arterial disease in the Hearts of Brazil Project. Arq Bras Cardiol 91:370-382.
26. Meyerfreund D, Goncalves C, Cunha R, et al. (2009) Agedependent increase in blood pressure in two different Native American communities in Brazil. J Hypertens 27:1753-1760.
27. Pavani A, Naushad SM, Rupasree Y, et al. (2011) Optimization of warfarin dose by population-specific pharmacogenomic algorithm. Pharmacogenomics J [Epub ahead of print]; Doi:10.1038/tpj.2011.4.
28. Pena SD, Di Pietro G, Fuchshuber-Moraes M, et al. (2011) The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS One 6:e17063.
29. Perera MA, Gamazon E, Cavallari LH, et al. (2011) The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 89:408-415.
30. Pimenta JR, Zuccherato LW, Debes AA, et al. (2006) Color and genomic ancestry in Brazilians: a study with forensic microsatellites. Hum Hered 62:190-195.
31. Rieder MJ, Reiner AP, Gage BF, et al. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285-2293.
32. Santos PC, Alvim Rde O, Ferreira NE, et al. (2011a) Ethnicity and arterial stiffness in Brazil. Am J Hypertens 24:278-284.
33. Santos PC, Gagliardi AC, Miname MH, et al. (2012) SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 68:273-279.
34. Santos PC, Soares RA, Krieger JE, et al. (2011b) Genotyping of the hemochromatosis HFE p. H63D and p. C282Y mutations by high-resolution melting with the Rotor-Gene 6000 ((R)) instrument. Clin Chem Lab Med 49:1633-1636.
35. Santos PC, Soares RA, Nascimento RM, et al. (2011c) SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group. BMC Med Genet 12:136.
36. Santos PC, Soares RA, Santos DB, et al. (2011d) CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet 12:13.
37. Schwarz UI, Ritchie MD, Bradford Y, et al. (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:999-1008.
38. Sconce EA, Khan TI, Wynne HA, et al. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient new dosing regimen. Blood 106:2329-2333.
39. Scott SA, Khasawneh R, Peter I, et al. (2011) Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 11:781-791.
40. Suarez-Kurtz G (2010) Pharmacogenetics in the brazilian population. Front Pharmacol 1:118.
41. Suarez-Kurtz G (2011) Population diversity and the performance of warfarin dosing algorithms. Br J Clin Pharmacol 72:451-453.
42. Vargens DD, Petzl-Erler ML, Suarez-Kurtz G (2011) Distribution of CYP2C Polymorphisms in an Amerindian Population of Brazil. Basic Clin Pharmacol Toxicol.
43. Wu AH (2007) Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics 8:851-861.
44. You JH (2011) Pharmacoeconomic evaluation of warfarin pharmacogenomics. Expert Opin Pharmacother 12:435-441.
45. Yuan HY, Chen JJ, Lee MT, et al. (2005) A novel functional VKORC1 promoter polymorphism is associated with interindividual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14:1745-1751.